COMPLYADVANTAGE
7.12.2021 07:02:05 CET | Business Wire | Press release
Raisin DS’s servicing bank, Raisin Bank AG, is teaming up with ComplyAdvantage, the leader in AI-driven financial crime risk detection, to scale its anti-money laundering (AML) program. On the heels of launching as a cloud bank, Raisin Bank needed a provider that could keep pace with fast growth. The scalable solutions offered by ComplyAdvantage across customer screening and monitoring as well as transaction monitoring will support Raisin Bank’s Banking-as-a-Service offerings.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211206005505/en/
Raisin Bank offers banking services including customer and account management, payment processing and loans for international start-ups and financial service providers. The servicing bank has been part of Raisin DS since its acquisition by the fintech in 2019.
Stricter regulations require agile solutions
Money laundering represents a growing challenge for financial service providers and authorities worldwide. As a result, regulatory requirements for banks in the area of anti-money laundering have been strengthened. Financial services organizations are required to implement complex control mechanisms to identify users, verify them and react to changes at short notice. In addition to trained staff, banks are therefore dependent on the latest technologies to effectively monitor customer applications and transactions.
ComplyAdvantage simplifies the monitoring process
ComplyAdvantage's AML solutions are helping fast-growing fintechs to meet these challenges. The company combines integration via a modern API with the latest regulatory technology innovations. Its customer screening and monitoring and transaction monitoring solutions enable Raisin Bank to make continuous improvements to its anti-money laundering procedures. ComplyAdvantage’s intuitive user interfaces also facilitates the work of the bank's anti-money laundering officers. The system decides whether to stop suspicious payments or to review them in more detail based on rules with versatile settings and customization options.
Perfect complement for Raisin Bank's core banking system
Traditionally, AML solutions are integrated into a bank’s software infrastructure and are difficult to improve beyond their initial capabilities. In contrast, ComplyAdvantage's application is connected to Raisin Bank's cloud-native core banking system via a standardized API and thus can be further developed and scaled independently. This enables ComplyAdvantage to fit perfectly with Raisin Bank's technological approach.
Dominik Zühlke, Chief Product Officer at Raisin Bank, comments: "In ComplyAdvantage we have found a reliable and competent partner for Raisin Bank. With their adaptable solutions, we can continually advance the efficacy of our anti-money laundering efforts. Both our companies share a common understanding of what Banking-as-a-Service needs to be: a combination of modern technological products with customer centric consulting and support that focuses on making their businesses thrive.”
Charles Delingpole, Founder & CEO at ComplyAdvantage, adds: “Raisin Bank epitomizes the type of hypergrowth fintech solution provider that our AML solutions are ideally designed for. With API’s for easy integration, state-of-the-art tooling for AML analysts and the seamless onboarding of customers, our goal has always been to build intelligent solutions that help businesses like Raisin Bank to transact with trust so they can grow with confidence.”
ComplyAdvantage And Raisin Bank Partner To Combine Award-Winning AML Technology With State-Of-The-Art BaaS Solutions
#bankingasaservice BaaS #compliance #financialcrime #AML #antimoneylaundering
About Raisin Bank
Raisin Bank AG targets Europe's fast-growing fintech community with a wide range of innovative, tailored and reliable services. Raisin Bank offers expert advice and efficient Banking-as-a-Service solutions, particularly in the processing of loan portfolios and the receivables of selected borrowers. As a fronting and service bank with a full banking license, Raisin Bank supports the implementation of business models that require a banking license. Raisin Bank’s clients include fintechs like Raisin DS, Creditshelf and Exporo, as well as family offices and funds in the areas of loans, deposits, accounts and payment transactions, among others. The bank has been operating under the Raisin Bank AG name since April 2019 and is a wholly owned subsidiary of Raisin DS GmbH.
About ComplyAdvantage
ComplyAdvantage is the financial industry’s leading source of AI-driven financial crime risk data and detection technology. ComplyAdvantage’s mission is to neutralize the risk of money laundering, terrorist financing, corruption, and other financial crime. More than 700 enterprises in 75 countries rely on ComplyAdvantage to understand the risk of who they’re doing business with through the world’s only global, real-time database of people and companies. The company actively identifies tens of thousands of risk events from millions of structured and unstructured data points every single day.
ComplyAdvantage has four global hubs located in New York, London, Singapore and Cluj-Napoca and is backed by Ontario Teachers’, Index Ventures and Balderton Capital. Learn more at complyadvantage.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211206005505/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
